Journal Article

A possible role of thrombin‐activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients

Tomasz Hryszko, Jolanta Malyszko, Jacek S. Malyszko, Szymon Brzosko, Krystyna Pawlak and Michal Mysliwiec

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 16, issue 8, pages 1692-1696
Published in print August 2001 | ISSN: 0931-0509
Published online August 2001 | e-ISSN: 1460-2385 | DOI:
A possible role of thrombin‐activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients

Show Summary Details


Background. Cardiovascular disease (CVD) is a major cause of death in renal transplant recipients (RTR). Suppression of fibrinolysis plays a role in the progression of atherosclerosis. Accelerated progression of atherosclerosis and fibrinolytic system suppression has been observed in RTR. Despite many years of intensive research, the reason for impaired fibrinolysis in this patient population is not fully understood. Thrombin‐activatable fibrinolysis inhibitor (TAFI) is a recently discovered glycoprotein combining coagulation and fibrinolysis. This study was conducted to evaluate concentrations of TAFI, markers of thrombin generation, endothelial injury, and some standard laboratory parameters in RTR receiving triple immunosuppressive drug regimen.

Methods. The study was performed in 29 stable, non‐diabetic kidney transplant recipients treated with cyclosporin A, azathioprine, and prednisone and in 18 age‐ and sex‐matched healthy volunteers. Soluble thrombomodulin (sTM), prothrombin fragments F1+2 (F1+2), thrombin–antithrombin complexes (TAT), plasmin–antiplasmin complexes (PAP), and TAFI were measured with commercially available kits.

Results. The RTR group had significantly higher plasma levels of TAT, F1+2, sTM and TAFI than the healthy volunteers. There were no differences in PAP concentrations between the two groups. Plasma sTM correlated inversely with creatinine clearance, body mass index, haemoglobin, and albumin. Plasma TAT level was positively associated with total cholesterol. TAFI antigen influenced negatively PAP antigen concentration.

Conclusions. On the basis of our research, we concluded that elevated circulating TAFI antigen might be a new link in the pathogenesis of impaired fibrinolysis in RTR, and thus atherosclerosis progression. In the patient group there is also evidence of endothelial injury, followed by secondary activation of the coagulation cascade. Hypercholesterolaemia in RTR is associated with enhanced thrombin activity.

Keywords: coagulation; cyclosporin A; endothelium injury; fibrinolysis; renal transplantation; thrombin‐activatable fibrinolysis inhibitor

Journal Article.  3080 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.